In new editorial, FDA's Califf says biomedical field should prioritize chronic illness, addiction

FDA Commissioner Robert Califf, M.D., has often been blunt and direct when outlining his goals and aspirations for the FDA since taking the helm for the second time earlier this year.

That trend continued in a new editorial Califf published Wednesday in Science, outlining his scientific priorities for the agency and how the biopharma industry should align with them. Specifically, he said companies and researchers should “review its priorities” and focus on developing more new treatments for common chronic diseases and addiction.